Alan J. Tackett

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy Federal Grant PI High Impact

IDeA National Resource for Quantitative Proteomics

UAMS primary UA Little Rock Hendrix College University of Arkansas

Also affiliated: Rutgers, The State University of New Jersey (2008); University of North Carolina at Chapel Hill (2020); University of Rome Tor Vergata (2016); Pennsylvania State University (2002); Johns Hopkins University (2009–2013); York College, City University of New York (2008); University of California, Los Angeles (2022); Vanderbilt University (2002–2020); University of Arkansas Medical Center (2015–2026); Johns Hopkins Medicine (2009–2013); Lebanon VA Medical Center (2013); Central Arkansas Veterans Healthcare System (2016–2018); UCLA Jonsson Comprehensive Cancer Center (2022); Arkansas Children's Research Institute (2018–2023); Penn State Milton S. Hershey Medical Center (2013); Rockefeller University (2003–2016)

Biochemistry & Molecular Biology, College of Medicine

52 h-index 1027 pubs 10,768 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Alan J. Tackett's research focuses on understanding fundamental molecular mechanisms, particularly those related to chromatin structure, gene regulation, and cancer development. He has investigated the roles of specific protein domains, such as PHD fingers, in binding to modified histones and influencing the activity of chromatin remodeling complexes like NURF and NuA3. His work has also explored the long-distance interactions and combinatorial linkages between histone modifications, such as methylation and acetylation, and their impact on gene expression.

Further research by Tackett has delved into the epigenetic modifications of DNA, including N6-adenine methylation in mammalian embryonic stem cells. He has also studied the aberrant chromatin looping and its connection to cancer development, as well as the potential for leveraging cancer-evolved resistance mechanisms to enhance therapeutic strategies. His federal funding includes significant support from the NIH/National Institute of General Medical Sciences for the IDeA National Resource for Quantitative Proteomics, as well as grants from the NIH/National Cancer Institute for identifying druggable targets in melanoma and enhancing EZH2 activity in adoptive T cells.

Tackett holds an h-index of 51 and has authored over 910 publications, with more than 10,718 citations. He is a member of the ARA Academy and has been recognized as a highly cited researcher. He leads a research group and maintains an active lab website, collaborating extensively with researchers at the University of Arkansas for Medical Sciences, including Samuel G. Mackintosh, Ricky D. Edmondson, Stephanie D. Byrum, and Aaron J. Storey.

Metrics

h-index: 52
Publications: 1027
Citations: 10,768

Positions

Distinguished Professor 2005–present

University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID
IDeA National Resource for Quantitative Proteomics publications 2000–2026

University of Arkansas for Medical Sciences Biochemistry & Molecular Biology, College of Medicine Institutional directory

Selected Publications

Repurposing Monensin and Its Derivatives as Immune-Modulatory Candidates for Metastatic Breast Cancer (Abstract ID: 231537) (2026)

DOI OpenAlex
Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection (2026)

DOI OpenAlex
Dynamic global acetylation remodeling during the yeast heat shock response (2026)

Genome biology 1 citation DOI OpenAlex
Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification (2025)

Nature Structural & Molecular Biology 4 citations DOI OpenAlex
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)

ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025)

Oncogene 7 citations DOI OpenAlex
BAHCC1 binds H4K20me1 to facilitate the MCM complex loading and DNA replication (2025)

Nature Communications 4 citations DOI OpenAlex
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025)

Journal of Thrombosis and Haemostasis 2 citations DOI OpenAlex
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)

iScience 1 citation DOI OpenAlex
The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators (2025)

Molecular Cell 27 citations DOI OpenAlex
Staphylococcus aureus Proteins Implicated in the Reduced Virulence of sarA and sarA/agr Mutants in Osteomyelitis (2025)

Microorganisms 6 citations DOI OpenAlex
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)

RSC Medicinal Chemistry 1 citation DOI OpenAlex
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)

Chemistry & Biodiversity 1 citation DOI OpenAlex
TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons (2023)

Nature 72 citations DOI OpenAlex
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma (2023)

Molecular Immunology 5 citations DOI OpenAlex

View all publications on OpenAlex →

ARA Academy 2021 ARA Fellow

Dr. Tackett leads a translational research team examining immunotherapy resistance in cancer treatment, specifically understanding why some patients show limited response to immunotherapies. His work combines research with clinical collaboration among oncologists, surgeons, and pathologists to develop new therapies for metastatic melanoma treatment.

Policy Impact

Advancing cancer immunotherapy research at the UAMS Rockefeller Cancer Institute, attracting federal funding and clinical collaborations that benefit cancer patients statewide.